Search

Petr A Ledin

from Beaverton, OR
Age ~39

Petr Ledin Phones & Addresses

  • 2529 NE Overlook Dr APT 237, Hillsboro, OR 97124
  • Beaverton, OR
  • Lake Forest, CA
  • Plantation, FL
  • Athens, GA

Work

Company: Georgia institute of technology Aug 2013 Position: Postdoctoral fellow

Education

School / High School: University of Georgia- Athens, GA 2013 Specialities: Ph.D. in Chemistry

Skills

Synthesis: multistep (>10) organic sy... • free radical (RAFT) and anionic polymeri... • solid phase peptide synthesis. Puri... • distillation • crystallization • dialysis • preparative size exclusion chromatograph... • high-performance liquid chromatography (... • 13C • COSY • HSQC • etc.) • mass-spectrometry (MALDI-TOF MS) • gel permeation chromatography (GPC) • infrared spectroscopy (FTIR • ATR-FTIR) • visible (Uv-Vis) and fluorescence spectr... • spectroscopic ellipsometry • dynamic light scattering (DLS) • transmission electron microscopy (TEM) • contact angle measurements • Langmuir-Blodgett technique. Specia... • Mestrelab Mnova • OriginLab Origin • Bruker NanoScope Analysis • J.A. Woollam VASE.

Resumes

Resumes

Petr Ledin Photo 1

Petr Ledin Atlanta, GA

View page
Work:
Georgia Institute of Technology

Aug 2013 to 2000
Postdoctoral Fellow

University of Georgia
Athens, GA
May 2008 to Aug 2013
Graduate Research Assistant

University of Georgia
Athens, GA
Aug 2007 to May 2008
Graduate Teaching Assistant at Department of Chemistry

Institute of Macromolecular compounds, Russian Academy of Sciences

May 2005 to Jul 2007
Undergraduate research Assistant

Education:
University of Georgia
Athens, GA
2013
Ph.D. in Chemistry

Petersburg State University
2007
B.S. in Chemistry

Skills:
Synthesis: multistep (>10) organic synthesis, free radical (RAFT) and anionic polymerizations (ROP), solid phase peptide synthesis. Purification: silica gel chromatography, distillation, crystallization, dialysis, preparative size exclusion chromatography (SEC), high-performance liquid chromatography (HPLC). Molecular characterization: nuclear magnetic resonance (NMR: 1H, 13C, COSY, HSQC, etc.), mass-spectrometry (MALDI-TOF MS), gel permeation chromatography (GPC), infrared spectroscopy (FTIR, ATR-FTIR), visible (Uv-Vis) and fluorescence spectroscopies. Materials characterization: atomic force microscopy (AFM), spectroscopic ellipsometry, dynamic light scattering (DLS), transmission electron microscopy (TEM), contact angle measurements, Langmuir-Blodgett technique. Specialized software: CambridgeSoft ChemOffice, Mestrelab Mnova, OriginLab Origin, Bruker NanoScope Analysis, J.A. Woollam VASE.

Publications

Us Patents

Methods Including Latent 1,3-Dipole-Functional Compounds And Materials Prepared Thereby

View page
US Patent:
20130310570, Nov 21, 2013
Filed:
Sep 27, 2011
Appl. No.:
13/876024
Inventors:
Geert-Jan Boons - Athens GA, US
Frederic Friscourt - Athens GA, US
Petr A. Ledin - Athens GA, US
Ngalle Eric Mbua - Athens GA, US
Assignee:
UNIVERSITY OF GEORIGA RESEARCH FOUNDATION, INC. - Athens GA
International Classification:
C07D 261/20
C07D 231/54
C07D 249/16
US Classification:
548241, 548259, 5483585, 435120, 435121
Abstract:
Methods that include latent 1,3-dipole-functional compounds are disclosed herein. The latent 1,3-dipole-functional compound (e.g., an oxime) can be used to form an active 1,3-dipole-functional compound (e.g., a nitrile oxide) that can be used to react with a cyclic alkyne in a dipolar cycloaddition reaction.

Modifications Of Therapeutic Agents For Enhanced Delivery To Target Sites

View page
US Patent:
20180028647, Feb 1, 2018
Filed:
Jul 26, 2017
Appl. No.:
15/660256
Inventors:
- Sunrise FL, US
Petr Ledin - Plantation FL, US
Tsukasa Mizuhara - Plantation FL, US
International Classification:
A61K 39/39
A61K 47/69
A61K 47/68
A61K 47/54
A61K 47/66
Abstract:
Compositions of a modulator of cell metabolism, typically targeting cellular glycolysis, preferably with a targeting moiety, attached directly or indirectly to the inhibitor, or to a nanoparticle or other delivery vehicle thereof, and methods of use for treating cancer, proliferative disorders, neurodegenerative diseases, autoimmune disorders, or inflammatory diseases are provided. Pharmaceutical compositions including the targeted modulator and a pharmaceutically acceptable carrier are also provided. The pharmaceutical compositions can be administered to a subject in need thereof in an effective amount to reduce one or symptoms of the cancer, proliferative disorders, neurodegenerative diseases, autoimmune disorders, or inflammatory diseases alone or prior to or in conjunction with a further therapy such as radiotherapy.
Petr A Ledin from Beaverton, OR, age ~39 Get Report